Simulations Plus, Inc.  

(Public, NASDAQ:SLP)   Watch this stock  
Find more results for SLP
9.95
-0.04 (-0.40%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.71 - 10.25
52 week 5.52 - 11.89
Open 10.18
Vol / Avg. 83,633.00/140,070.00
Mkt cap 166.64M
P/E 38.51
Div/yield 0.05/2.01
EPS 0.26
Shares 16.97M
Beta -0.06
Inst. own 24%
Apr 12, 2016
Q2 2016 Simulations Plus Inc Earnings Release (Estimated) Add to calendar
Jan 14, 2016
Q1 2016 Simulations Plus Inc Earnings Call - Webcast
Jan 14, 2016
Q1 2016 Simulations Plus Inc Earnings Release
Nov 18, 2015
Q4 2015 Simulations Plus Inc Earnings Call - Webcast
Nov 18, 2015
Q4 2015 Simulations Plus Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Nov '15) 2015
Net profit margin 22.87% 20.98%
Operating margin 35.70% 31.98%
EBITD margin - 33.94%
Return on average assets 16.05% 15.90%
Return on average equity 22.49% 21.98%
Employees 57 -
CDP Score - -

Address

42505 10th St W
LANCASTER, CA 93534-7059
United States - Map
+1-661-7237723 (Phone)
+1-661-7235524 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

Officers and directors

Walter S. Woltosz Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thaddeus Henry Grasela Jr President, Director
Age: 61
Bio & Compensation  - Reuters
John R. Kneisel CPA Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
John A. DiBella II Vice President - Sales & Marketing
Age: 35
Bio & Compensation  - Reuters
David Z. D'Argenio Independent Director
Age: 65
Bio & Compensation  - Reuters
John Kenneth Paglia Independent Director
Age: 48
Bio & Compensation  - Reuters
David L. Ralph Independent Director
Age: 68
Bio & Compensation  - Reuters